• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP News SCAN: More romaine E coli; Polio in 6 countries; MERS vaccine trial

Shiloh

Editor, Senior Moderator
Source: http://www.cidrap.umn.edu/news-perspective/2019/12/news-scan-dec-20-2019

News Scan for Dec 20, 2019
More romaine E coli; Polio in 6 countries; MERS vaccine trial

Filed Under:
E coli; Foodborne Disease; Polio; MERS-CoV


[h=3]Multistate E coli outbreak tied to romaine lettuce grows to 138 cases[/h] The multistate outbreak of Escherichia coli O157:H7 infections tied to contaminated romaine lettuce has grown by 36 illnesses, for a total of 138 cases in 25 states, the Centers for Disease Control and Prevention (CDC) said in an update yesterday.
Seventy-two of the patients (52%) were sick enough to need hospitalization, the CDC said, and 13 have hemolytic uremic syndrome, a type of kidney failure. None of the infected people have died. South Carolina and Tennessee reported their first outbreak cases.
"CDC continues to advise that consumers not eat and retailers not sell any romaine lettuce grown in the Salinas, California, growing region," the agency said. "This includes all use-by dates and brands of romaine lettuce from this region."
Illness-onset dates range from Sep 20 to Dec 1, but some people who got sick after that might not yet be reported. The patients vary in age from less than 1 to 89 years, with a median age of 26; 62% are female.
The Wisconsin Department of Health Services recently identified the outbreak strain of E coli in an unopened bag of Fresh Express Leafy Green Romaine containing romaine from the Salinas region that officials had collected from a case-patient's home.
Wisconsin is the hardest-hit state, with 33 cases, followed by Pennsylvania (17), Ohio (12), and Illinois (10).
Dec 19 CDC update

[h=3]Six countries report more wild and vaccine-linked polio cases[/h] Six countries have reported 33 new polio cases combined, according to the latest weekly update from the Global Polio Eradication Initiative (GPEI).
Two of the countries reported new wild poliovirus type 1 (WPV1) cases—2 in Afghanistan and 7 in Pakistan, where gunmen in northwestern Khyber Pakhtunkhwa province on Dec 18 killed two police officers who were guarding polio vaccinators.
Afghanistan's cases are from Uruzgan and Baghlan provinces, lifting the country's total for the year to 24. Pakistan's cases are in Sindh and Khyber Kakhtunkhwa provinces, bringing its number for the year to 101.
Meanwhile, Pakistan and four African countries reported more circulating vaccine-derived poliovirus type 2 (cVDPV2) cases. Pakistan reported 1 new case, pushing its number of vaccine-linked cases to 12. In Africa, countries reporting more cVDPV2 cases are Angola (11), the Democratic Republic of the Congo (8), Ghana (3), and Chad (1).
Dec 20 GPEI update
Dec 18 Voice of America story on Pakistan attack


[h=3]MERS vaccine trial launches in Saudi Arabia[/h] Saudi Arabia and the University of Oxford's Jenner Institute yesterday announced the launch of a phase 1 clinical trial of a MERS-CoV vaccine, the first of its kind to be conducted in Saudi Arabia.
The study involves ChAdOx1 MERS, a replication-deficient simian adenoviral-vectored vaccine, which is being developed by Oxford University and Janssen Vaccines. An initial phase 1 trial has been under way in the United Kingdom, and the vaccine has received support from the UK government and the Coalition for Epidemic Preparedness Innovations (CEPI).
In Saudi Arabia, the MERS-CoV (Middle East respiratory syndrome coronavirus) vaccine trial will replicate the design of the one in the UK, testing the vaccine in 24 healthy volunteers ages 18 to 50 years old.
In a news release, Oxford said the trial at Saudi Arabia's King Abdullah International Medical Research Center and King Abdulaziz Medical Center in Riyadh will provide additional data to support phase 1 findings. The university added that conducting a clinical trial in an endemic region is an important step in vaccine development.
Dec 19 University of Oxford press release
 
Back
Top Bottom